Tongshang advises the US$398M Hong Kong IPO of Keymed Biosciences Inc.
Commerce & Finance Law Offices ("Tongshang") represented the joint sponsors and underwriters in the successful listing of Keymed Biosciences Inc. (HKEX:2162) (KEYMED BIO-B) on the Main Board of the Stock Exchange of Hong Kong (HKEX), which raised approximately HK$3.1 billion (US$398 million).
Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited and Huatai Financial Holdings (Hong Kong) Limited were the joint sponsors for the IPO. Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and China Everbright Securities (HK) Limited acted as the Hong Kong underwriters.
Keymed Biosciences Inc. is a biotechnology company focused on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas.
Tongshang IPO practice continues to be one of the leaders in the Hong Kong IPO market. According to latest data from Ryanben Capital, Tongshang was the no. 1 legal adviser to PRC law in the Hong Kong IPO league table by deal volume in the past 6 months (January – June 2021).